Matches in UGent Biblio for { <https://biblio.ugent.be/publication/3135432#aggregation> ?p ?o. }
Showing items 1 to 36 of
36
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B794447.
- aggregation creator B794448.
- aggregation creator B794449.
- aggregation creator B794450.
- aggregation creator person.
- aggregation date "2011".
- aggregation format "application/pdf".
- aggregation hasFormat 3135432.bibtex.
- aggregation hasFormat 3135432.csv.
- aggregation hasFormat 3135432.dc.
- aggregation hasFormat 3135432.didl.
- aggregation hasFormat 3135432.doc.
- aggregation hasFormat 3135432.json.
- aggregation hasFormat 3135432.mets.
- aggregation hasFormat 3135432.mods.
- aggregation hasFormat 3135432.rdf.
- aggregation hasFormat 3135432.ris.
- aggregation hasFormat 3135432.txt.
- aggregation hasFormat 3135432.xls.
- aggregation hasFormat 3135432.yaml.
- aggregation isPartOf urn:issn:0804-4643.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics".
- aggregation abstract "Objective: GH replacement therapy currently requires daily injections, which may be inconvenient and distressing for young patients. This study determined the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single doses of a pegylated GH (NNC126-0083) developed for once-weekly administration, in children with GH deficiency (GHD). Design and methods: Thirty children (age >= 6 and <= 12 years, weight >= 16 kg) were randomised to NNC126-0083 or daily GH treatment. The subjects discontinued their daily GH treatment 7-9 days before receiving NNC126-0083 at 0.01, 0.02, 0.04 or 0.06 mg protein/kg (n = 22) or seven once-daily doses of GH at 0.035 mg protein/kg (n = 8). Results: NNC126-0083 was well tolerated, and no short-term safety or local tolerability issues were identified. After NNC126-0083 treatment, dose-dependent IGF1 increases were evident for maximum concentration (C(max)), but not area under the curve (AUC(0-168 h)). Mean values for IGF1 AUC(0-168h)/168 h and C(max) were higher for GH than for NNC126-0083, although the difference was not statistically significant for cohort's 0.06 mg protein/kg. At 0.06 mg protein/kg, the resulting IGF1 response began subsiding at similar to 3 days post-dose. Conclusion: Single doses of long-acting NNC126-0083 were safe and well tolerated in children with GHD. Increased IGF1 levels were observed in all NNC126-0083 dose groups; however, a satisfactory once-weekly IGF1 profile was not reached within the NNC126-0083 dose levels administered.".
- aggregation authorList BK1165926.
- aggregation endPage "409".
- aggregation issue "3".
- aggregation startPage "401".
- aggregation volume "165".
- aggregation aggregates 3135449.
- aggregation isDescribedBy 3135432.
- aggregation similarTo EJE-11-0536.
- aggregation similarTo LU-3135432.